Miraculins to Launch PreVu(R) in Canada Through London Drugs

WINNIPEG, MANITOBA--(Marketwire - Aug. 13, 2012) - Miraculins Inc., (MOM.V) a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces today an agreement with London Drugs, one of Canada's leading pharmacy chains, and Pear Healthcare Solutions, that will see the retail pharmacy launch of its PreVu(R) Non-Invasive Skin Cholesterol Point of Care (POC) Test take place in up to ten London Drugs locations in Vancouver and the Lower Mainland, planned for October 2012.

"This pilot program is a very significant milestone for PreVu in Canada, as well as a major step forward in the commercialization of the technology worldwide," said Paul Moreau, Vice President, Sales and Marketing for Miraculins Inc. "We are very pleased that London Drugs, a highly respected retail brand in the healthcare services sector, wants to make the PreVu POC Test available to its customers to help them better understand their risk of coronary artery disease (CAD). With over 70,000 heart attacks in Canada each year, resulting in over 16,000 deaths, this pilot program represents an important development towards realizing better heart health for all Canadians at risk."

As part of the agreement, London Drugs will have an option to expand the PreVu POC Test into all 74 London Drugs stores as an ongoing service, following the completion of the pilot program. London Drugs operations extend from British Columbia to Manitoba, and the subsequent introduction of PreVu throughout its full network of stores - anticipated to begin in early 2013 - would be associated with a period of market exclusivity for London Drugs, in delivering the technology through its retail pharmacy platform into the Western Canadian marketplace.

"We have a longstanding tradition of bringing new, innovative and meaningful technologies to our customers and we are most impressed with the science behind the PreVu POC Test," said John Tse, Vice President, Pharmacy for London Drugs. "We believe our customers will benefit from experiencing this convenient, rapid and non-invasive skin cholesterol test and that it can serve to help them begin to gain greater understanding and management of the risk factors they may unknowingly be living with for CAD."

The pilot program will incorporate the PreVu POC Test into specially designed CAD risk assessment clinics that will be conducted in-pharmacy and supported by Pear Healthcare Solutions, a leading provider of in-pharmacy health screening and education to the Canadian pharmacy community and the exclusive distributor of the PreVu POC Test to this same market segment.

"We are very pleased to be working with London Drugs on this pilot program to better serve the health needs of its customers, and to provide the organization with a competitive distinction in the marketplace by introducing tailored CAD risk assessment programming into its stores featuring the PreVu POC Test," said Mark Doyle, Vice President, Sales and Marketing for Pear Healthcare Solutions.

Further details about the pilot program will be announced closer to the fall launch.

Miraculins recently announced the allowance of key patents for its PreVu technology in the U.S. and China - both anticipated to be major markets for the test - and has launched a new English language website for PreVu for the Canadian marketplace (www.prevu.com), with a mirror site in the French language currently under development.

About The PreVu(R) Non-Invasive Skin Cholesterol Test

The PreVu(R) Point of Care (POC) Test is a non-invasive, risk assessment technology designed to measure Skin Cholesterol - an important new biomarker in assessing risk of coronary artery disease (CAD). The PreVu POC Test is completely painless, non-invasive, involves no blood draw or needles, and requires no overnight fasting. This in vitro diagnostic test is conducted on the palm of the hand in less than 5 minutes with results being immediately available, facilitating point of care consultation and a next steps discussion. Skin Cholesterol is the cholesterol that has been deposited and diffused into tissue, as opposed to freely circulating in the bloodstream, and the skin contains approximately 11% of all the cholesterol found in the human body. Elevated Skin Cholesterol has been shown in clinical studies to be strongly associated with significant CAD as measured by treadmill stress testing and coronary angiography, as well as measured by testing for coronary calcium, carotid artery thickening, and carotid artery plaque. The PreVu POC Test does not diagnose the presence or absence of CAD, but helps to identify patients who may be at higher, hidden risk for CAD by measuring this new biomarker. For more information visit http://www.prevu.com.

See more here:
Miraculins to Launch PreVu(R) in Canada Through London Drugs